Clinical Trials in Progress Submission 

Clinical Trials in Progress Submission Instructions

​

• Have you organised a novel clinical trial pertaining to hepatopancreatobiliary diseases?

• Are you currently accruing patients to an HPB trial?

• Are you looking to connect with other institutions or investigators to broaden the accrual of a clinical trial in progress?

• Have you got early breaking results?

​

At the upcoming E-AHPBA 2025 Congress, you will have an opportunity to present your work in one of the Clinical Trials in Progress Sessions within the main scientific programme. Following a competitive selection process, trials will be presented by their investigators with vibrant discussion and feedback. These sessions will provide a forum for sharing ideas, publicising trials seeking extramural participation, and promoting early results or findings.

 

Trials will be eligible for an Oral Presentation if they meet the following criteria:

​

• Trials must be accruing or have patients under study follow-up

• Trial results may not have been published at the time of presentation

• Trials must be clinically focused and may include therapeutic, palliative, or diagnostic modalities

• Preliminary results, outcomes, and endpoints may be presented

 

The deadline for submission of abstracts to be considered for a Clinical Trials in Progress session is 8th April 2025. There will not be any extension to this date.

 

The E-AHPBA Scientific Programme Committee look forward to these exciting updates in your ongoing clinical trials. General Information

​

• Trials should be submitted electronically through the link available on the Congress website.

• The abstract must be written in English and limited to 250 words.

• 1 Table and/or Image may be included in the abstract.

• If you do not complete the submission process, your information will be held in “draft” until you return later to complete your submission. Please note that your trial must be fully submitted before the deadline of 8th April 2025 to be considered for the Congress.

• Changes are possible until 8th April 2025 through your personal “My Submissions” page, which can be accessed with the link included in the electronic acknowledgement of receipt.

• The submitting author will receive all correspondence concerning the trial and is responsible for informing the other co-authors of the abstract status.

• Acknowledgement of abstract submission will be sent to the stated email address. If you do not receive the confirmation within 24 hours of submission, please contact E-AHPBA 2025 Abstract Department at eahpba.abstracts@abstractserver.com.

• Notification of acceptance/rejection of the abstracts will be emailed to the submitting author on or after 11th April 2025.

• Submission of your abstract constitutes your consent to transfer the abstract to an alternative theme/session if the Scientific Programme Committee considers this to be more appropriate.

• Upon acceptance of the abstract, all presenting authors are expected to register and present in person at the Congress.

 

Should you have any questions, please contact eahpba.scientific@eahpba.org.